title: Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study.
abstract: BACKGROUND
  Prokinetic agents have shown variable efficacy in the treatment of functional dyspepsia. Mosapride is a new prokinetic 5-hydroxytryptamine-4 agonistic agent.
  
  
  OBJECTIVE
  To evaluate the efficacy of three dosage regimens of mosapride compared with placebo in the treatment of functional dyspepsia.
  
  
  METHODS
  Patients were randomly allocated to treatment with placebo or mosapride (5 mg b.d., 10 mg b.d. or 7.5 mg t.d.s.) in a double-blind, prospective, multicentre, multinational study. The change in symptom severity score from an untreated baseline week to the sixth week of treatment was used to compare treatment efficacy.
  
  
  RESULTS
  There were 141, 140, 143 and 142 patients valid for evaluation in the intention-to-treat population in the placebo, mosapride 5 mg b.d., mosapride 10 mg b.d. and mosapride 7.5 mg t.d.s. groups, respectively. The mean changes in the overall dyspeptic symptom score were - 0.90, - 0.94, - 0.88 and - 0.89, respectively, and the proportions of patients feeling better at the end of the treatment period were 60%, 59%, 59% and 61%, respectively. No statistically significant difference was seen.
  
  
  CONCLUSIONS
  Treatment of functional dyspepsia with mosapride was not superior to placebo. The result raises the question of whether treatment with prokinetic agents is appropriate for functional dyspepsia.
authors.affiliation: Surgical Department, NAL, Trollhättan, Sweden, CHU Clermont Ferrand, Dieu, France. bengt.hallerback@vgregion.se
authors.forename: B I
authors.initials: BI
authors.lastname: Hallerbäck
authors.forename: G
authors.initials: G
authors.lastname: Bommelaer
authors.forename: E
authors.initials: E
authors.lastname: Bredberg
authors.forename: M
authors.initials: M
authors.lastname: Campbell
authors.forename: M
authors.initials: M
authors.lastname: Hellblom
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: M
authors.initials: M
authors.lastname: Wienbeck
authors.forename: L-L
authors.initials: LL
authors.lastname: Holmgren
mesh_terms: D000328:Adult; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride